Trials / Completed
CompletedNCT01908816
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 270 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab | One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN) |
Timeline
- Start date
- 2013-09-26
- Primary completion
- 2016-01-08
- Completion
- 2016-01-08
- First posted
- 2013-07-26
- Last updated
- 2019-08-12
- Results posted
- 2019-08-12
Locations
39 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01908816. Inclusion in this directory is not an endorsement.